Azitra (NYSE: AZTR) sets June 15 date to reconvene 2026 virtual annual meeting
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Azitra, Inc. is postponing the business of its 2026 annual stockholders’ meeting due to a minor administrative delay in mailing proxy materials. The company will open the meeting on June 4, 2026 at 11:00 a.m. Eastern Time and immediately adjourn it without conducting other business.
The annual meeting will reconvene virtually on June 15, 2026 at 11:00 a.m. Eastern Time at www.proxydocs.com/AZTR. The record date remains April 24, 2026, and the proposals to be voted on are unchanged. Stockholders who already voted and do not wish to change their vote do not need to take further action.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Initial 2026 annual meeting date: June 4, 2026, 11:00 a.m. Eastern Time
Reconvened annual meeting date: June 15, 2026, 11:00 a.m. Eastern Time
Proxy voting cutoff: June 15, 2026, 10:59 a.m. Eastern Time
+3 more
6 metrics
Initial 2026 annual meeting date
June 4, 2026, 11:00 a.m. Eastern Time
Scheduled time to convene and immediately adjourn the 2026 annual meeting
Reconvened annual meeting date
June 15, 2026, 11:00 a.m. Eastern Time
Time the 2026 annual meeting will reconvene virtually
Proxy voting cutoff
June 15, 2026, 10:59 a.m. Eastern Time
Deadline for advance proxy votes to be received before the reconvened meeting
Record date
April 24, 2026
Date for determining stockholders entitled to vote at the adjourned meeting
EGFRi rash population
Approximately 150,000 people in the U.S.
Estimated number of people affected by EGFR inhibitor associated rash targeted by ATR-04
Microbial library size
Approximately 1,500 bacterial strains
Size of Azitra’s proprietary microbial library used in its platform
Key Terms
Fast Track designation, Netherton syndrome, EGFR inhibitor (EGFRi) associated rash, Investigational New Drug (IND), +2 more
6 terms
Fast Track designation regulatory
"Azitra has received Fast Track designation from the FDA for EGFRi associated rash"
A "fast track designation" is a process that speeds up the review and approval of a product or project, allowing it to reach the market or be completed more quickly than usual. For investors, it can signal that a product may become available sooner, potentially leading to earlier revenue or benefits, and indicating a priority status that might influence company performance and market opportunities.
Netherton syndrome medical
"ATR-12 ... designed to treat Netherton syndrome, a rare, chronic skin disease"
A rare inherited skin and immune disorder that causes fragile, scaly, inflamed skin, frequent infections, and fragile or unusual hair, like a house with faulty waterproofing that lets problems in. For investors, it matters because the small patient population, severe unmet medical need, and predictable biological cause can make treatments eligible for special regulatory incentives, faster development paths, and premium pricing if a safe, effective therapy is approved.
EGFR inhibitor (EGFRi) associated rash medical
"ATR-04 ... for the treatment of EGFR inhibitor (“EGFRi”) associated rash"
Investigational New Drug (IND) regulatory
"Azitra has an open IND for its ATR-04 program in patients with EGFRi associated rash"
An investigational new drug (IND) is a drug or biologic that is being tested but has not yet been approved for general use; it is the application and formal status that allows a company to begin human clinical trials under regulator oversight. Investors care because an IND marks the transition from lab work to human testing — like getting a permit to run real-world experiments — which creates important milestones, costs, timelines and regulatory risk that drive a development-stage company's value.
live biotherapeutic products medical
"topical live biotherapeutic products that includes a microbial library"
Live biotherapeutic products are medicines made from live microorganisms intended to prevent, treat or cure disease, administered to people under medical oversight. Think of them like highly regulated, medicinal versions of probiotics: they can offer new ways to address illnesses but also bring special risks and costs — strict regulatory approval, complex manufacturing (imagine precision brewing), storage and batch consistency — all of which can significantly affect clinical success and investor returns.
proxy statement financial
"stockholders may cast their votes by following instructions set forth in the Company’s definitive proxy statement on Schedule 14A"
A proxy statement is a document companies send to shareholders ahead of a meeting that lays out the items up for a vote—like who will sit on the board, executive pay, and major corporate decisions—and provides background so shareholders can decide how to cast their votes or appoint someone to vote for them. Think of it as an agenda plus a ballot and briefing notes, important because the outcomes can change control, strategy, and value.
FAQ
Why is Azitra (AZTR) adjourning its 2026 annual meeting?
Azitra is adjourning its 2026 annual meeting because of a minor administrative delay in mailing proxy materials. The adjournment gives stockholders more time to receive, review, and submit their proxies before voting on the existing meeting proposals.
When will Azitra’s 2026 annual meeting reconvene and how can I attend?
Azitra’s 2026 annual meeting will reconvene on June 15, 2026 at 11:00 a.m. Eastern Time. Stockholders can attend virtually at www.proxydocs.com/AZTR using the control number included in their proxy card to listen, vote, and submit questions.
What is the record date to vote at Azitra’s reconvened 2026 annual meeting?
The record date to determine who can vote at Azitra’s reconvened 2026 annual meeting remains April 24, 2026. Only stockholders of record as of the close of business on that date are entitled to vote on the meeting proposals.
Do Azitra stockholders need to vote again after the 2026 meeting adjournment?
Stockholders who already submitted a proxy and do not want to change their vote do not need to act. Their previous votes remain valid for the reconvened meeting and will be counted according to their earlier instructions.
Will Azitra’s 2026 annual meeting proposals change after the adjournment?
No changes have been made to the proposals to be voted on at Azitra’s 2026 annual meeting. The reconvened meeting on June 15, 2026 will consider the same proposals originally described in the company’s 2026 Annual Meeting Proxy Statement.